Eli Lilly’s third-to-market migraine prevention drug Emgality has a lot of ground to make up on its rivals, but a new study in people who have failed earlier migraine therapies could help.

Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality but could get a leg-up with an indication in episodic cluster headache.